PA
CYTO

Perceptive Advisors’s Altamira Therapeutics Ltd CYTO Stock Holding History

Perceptive Advisors’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5
Closed -$368K – 162
2017
Q1 		$368K Buy
+5
New +$401K 0.02% 127

Other funds holding CYTO

SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Perceptive Advisors's CYTO Position: Q2 2017 in Review

Perceptive Advisors sold out of Altamira Therapeutics Ltd (CYTO) in Q2 2017, closing a stake of 5 shares — an estimated $368K sold.

Perceptive Advisors first reported a position in CYTO in Q1 2017 and held it in 1 quarter. The position peaked at $368K in Q1 2017. 9 funds tracked by Wall St. Rank hold CYTO as of Q2 2017.

  • Perceptive Advisors reported no remaining Altamira Therapeutics Ltd position as of Q2 2017 after selling out during the quarter.
  • Perceptive Advisors sold 5 Altamira Therapeutics Ltd shares in Q2 2017, an estimated $368K.
  • Perceptive Advisors first reported a position in Altamira Therapeutics Ltd in Q1 2017 and held it in 1 quarter.
  • Perceptive Advisors's Altamira Therapeutics Ltd position peaked at $368K in Q1 2017.
  • 9 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.